Bath Savings Trust Co Sells 32,577 Shares of Edwards Lifesciences Co. (NYSE:EW)

Bath Savings Trust Co lessened its position in Edwards Lifesciences Co. (NYSE:EW) by 62.0% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 19,977 shares of the medical research company’s stock after selling 32,577 shares during the period. Bath Savings Trust Co’s holdings in Edwards Lifesciences were worth $1,479,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. FSA Wealth Management LLC bought a new position in Edwards Lifesciences in the 3rd quarter valued at $30,000. Prospera Private Wealth LLC bought a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at $32,000. Avior Wealth Management LLC lifted its holdings in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after buying an additional 308 shares in the last quarter. Peoples Bank KS purchased a new stake in Edwards Lifesciences in the 3rd quarter worth approximately $40,000. Finally, JFS Wealth Advisors LLC raised its position in shares of Edwards Lifesciences by 31.1% in the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after buying an additional 166 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 2,500 shares of Edwards Lifesciences stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 37,500 shares of company stock valued at $2,508,350. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 0.8 %

Shares of EW traded up $0.60 during mid-day trading on Tuesday, reaching $74.14. The company had a trading volume of 1,130,095 shares, compared to its average volume of 3,683,541. The firm has a fifty day simple moving average of $71.18 and a 200-day simple moving average of $72.41. The stock has a market cap of $43.73 billion, a price-to-earnings ratio of 10.70, a price-to-earnings-growth ratio of 3.63 and a beta of 1.11. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.59 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Piper Sandler cut their price objective on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a report on Friday, October 25th. UBS Group lowered their price target on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a research report on Tuesday, September 10th. Jefferies Financial Group cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their target price for the stock from $85.00 to $70.00 in a research report on Wednesday, September 18th. Wells Fargo & Company reduced their price target on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Finally, The Goldman Sachs Group raised their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Sixteen research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and an average target price of $79.40.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.